Probiotics for the oncological patients
The main objective of this project is to perform the technological/comercial and economical viability of the newly developped very gentle form of microbial lysis which preserves the biologically active molecules of probiotic bacteria that favorably affects the cells of the intestinal mucosa and the mucosal immune system. This newly designed probioticsmodify the integrity of the intestinal mucosa damaged as a result of oncological treatment, to suppress inflammatory changes in the mucous membrane and, at the same time, to contribute to stabilization by the treatment of the disrupted microbiome.  The ONCOTICS introduces novel treatment of intestines infections which brings :  - Unique probiotical lysates product improving the oncology patients life comfort  -  New approach for elemination of syndrom leaky gut in oncological patients  -  Very safe gut barrier regeneration compared with standard probiotics, which can cuase sepsis  -  New patented technology for production of probiotics lysates  -  Novel therapy opening new markets